Product Details
Place of Origin: China
Brand Name: Quickoolchem
Payment & Shipping Terms
Minimum Order Quantity: 50 Grams
Price: Negotiable
Packaging Details: 1~10 KG Aluminum Foil Bag, 25KG/drum
Delivery Time: 1-3 working day
Payment Terms: L/C, L/C, D/A, D/P, T/T, Western Union, MoneyGram
Supply Ability: 10 MT/Month
Apperance: |
White Powder |
Product Name: |
Molnupiravir (EIDD-2801) |
Storage: |
Store In A Cool, Dry Place |
Cas: |
2349386-89-4 |
Grade: |
Pharmaceutcial Grade |
Test: |
HPLC |
Assay: |
99.9% |
Country Of Origin: |
China |
Apperance: |
White Powder |
Product Name: |
Molnupiravir (EIDD-2801) |
Storage: |
Store In A Cool, Dry Place |
Cas: |
2349386-89-4 |
Grade: |
Pharmaceutcial Grade |
Test: |
HPLC |
Assay: |
99.9% |
Country Of Origin: |
China |
Molnupiravir powder is the powdered form of the antiviral drug Molnupiravir (also known as EIDD-2801). Molnupiravir is chemically known as β-D-N^4-hydroxycytidine. It is a prodrug, meaning it is metabolized in the body to its active form, N^4-hydroxycytidine triphosphate, which then inhibits viral RNA polymerase, preventing viral replication.
Molnupiravir works by inducing mutations in the viral RNA during replication, leading to an accumulation of errors that inhibit the virus's ability to replicate effectively. This mechanism makes it effective against a wide range of RNA viruses, including influenza viruses, coronaviruses, and others.
Product Name | Molnupiravir (EIDD-2801) |
---|---|
Molecular Formula | C13H19N3O7 |
Molecular Weight | 329.31 |
Assay | 99.9% |
Grade | Pharmaceutical Grade |
Cas | 2349386-89-4 |
Grade Standard | Pharmaceutical Grade |
Test | HPLC |
Appearance | White Powder |
Storage | Store In A Cool, Dry Place |
1. Treatment of Viral Infections: Molnupiravir has shown efficacy against a range of RNA viruses, including influenza viruses and coronaviruses like SARS-CoV-2. It can be used to treat viral infections in patients who are symptomatic or at risk of developing severe disease.
2. Antiviral Prophylaxis: Molnupiravir may be used as a prophylactic treatment to prevent viral infections in individuals who are at high risk of exposure, such as healthcare workers or individuals living in close quarters with infected individuals.
3. Pandemic Response: Molnupiravir has garnered significant attention as a potential treatment for pandemics, including the COVID-19 pandemic. Its oral administration and broad-spectrum antiviral activity make it a promising candidate for controlling outbreaks of emerging viral diseases.
4. Research and Development: Molnupiravir powder can also be used in preclinical and clinical research studies to further understand its mechanism of action, assess its efficacy against different viral strains, and explore potential combination therapies.